Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | INBRX-105 |
Synonyms | |
Therapy Description |
INBRX-105 (ES 101) is a bispecific antibody that binds to TNFRSF9 (CD137) and PD-L1 (CD274), potentially resulting in enhanced anti-tumor immunity and tumor cell lysis (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
INBRX-105 | INBRX105|INBRX 105|ES 101|ES-101|ES101 | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 122 TNFRSF9 Antibody 32 | INBRX-105 (ES 101) is a bispecific antibody that binds to TNFRSF9 (CD137) and PD-L1 (CD274), potentially resulting in enhanced anti-tumor immunity and tumor cell lysis (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03809624 | Phase II | INBRX-105 INBRX-105 + Pembrolizumab | Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer (PDL1x41BB) | Terminated | USA | 0 |